Casetti et al., 2022 - Google Patents
COVID-19 in patients with hematologic diseasesCasetti et al., 2022
View HTML- Document ID
- 2420906035695716221
- Author
- Casetti I
- Borsani O
- Rumi E
- Publication year
- Publication venue
- Biomedicines
External Links
Snippet
The COVID-19 outbreak had a strong impact on people's lives all over the world. Patients with hematologic diseases have been heavily affected by the pandemic, because their immune system may be compromised due to anti-cancer or immunosuppressive therapies …
- 200000000015 coronavirus disease 2019 0 title abstract description 175
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan | Norovirus vaccines: current clinical development and challenges | |
| Mingot-Castellano et al. | COVID-19 vaccines and autoimmune hematologic disorders | |
| Agbarya et al. | Efficacy of the mRNA-based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs | |
| Kudlay et al. | Peculiarities of the T cell immune response in COVID-19 | |
| Casetti et al. | COVID-19 in patients with hematologic diseases | |
| Yen et al. | COVID-19 vaccines in patients with maintenance hemodialysis | |
| Matyushenko et al. | Detection of IFNγ-secreting CD4+ and CD8+ memory T cells in COVID-19 convalescents after stimulation of peripheral blood mononuclear cells with live SARS-CoV-2 | |
| Kocivnik et al. | A review pertaining to SARS-CoV-2 and autoimmune diseases: what is the connection? | |
| Pappa et al. | A Phase II study on the use of convalescent plasma for the treatment of severe COVID-19-a propensity score-matched control analysis | |
| Park et al. | Association of cerebral venous thrombosis with mRNA COVID-19 vaccines: a disproportionality analysis of the World Health Organization pharmacovigilance database | |
| Martynova et al. | Long term immune response produced by the SputnikV vaccine | |
| Hajjo et al. | Analyzing the systems biology effects of COVID-19 mRNA vaccines to assess their safety and putative side effects | |
| Tepasse et al. | Vaccination against SARS-CoV-2 in patients with inflammatory bowel diseases: where do we stand? | |
| Yang et al. | Developing an effective peptide-based vaccine for COVID-19: Preliminary studies in mice models | |
| Goel et al. | Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield®) in patients with liver cirrhosis | |
| Echaide et al. | Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination | |
| Guetl et al. | Thrombotic complications after COVID-19 vaccination: diagnosis and treatment options | |
| Abarca et al. | Safety and non-inferiority evaluation of two immunization schedules with an inactivated SARS-coV-2 vaccine in adults: A randomized clinical trial | |
| Silva et al. | The relationship between TLR3 rs3775291 polymorphism and infectious diseases: A meta-analysis of case-control studies | |
| Cheng et al. | The humoral immune response of the ChAdOx1 nCoV-19 vaccine in maintenance dialysis patients without prior COVID-19 infection | |
| Hus et al. | COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic | |
| Lin et al. | Vaccine-induced immune thrombotic thrombocytopenia following BNT162b2 mRNA COVID-19 booster: a case report | |
| Tuyji Tok et al. | One-year post-vaccination longitudinal follow-up of quantitative SARS-CoV-2 anti-spike total antibodies in health care professionals and evaluation of correlation with surrogate neutralization test | |
| Arias et al. | Biologics in COVID-19 so far: systematic review | |
| Cavanna et al. | COVID-19 vaccination in cancer patients older than 70 years undergoing active treatment. Seroconversion rate and safety |